Looking to buy the report?


Degenerative disc disease is used to describe the regular changes that occur in human spinal discs as they age. The discs usually act as shock absorbers for the human spine, which allows the body to flex, bend, and twist. With aging, there are several other factors, such as the drying out of the disc, tears in the outer core of the disc during daily activities, and sports and injuries leading to swelling, soreness, and instability, contributing to the development of degenerative disc disease.

This disease often leads to multiple types of disorders, such as lumbar spinal stenosis, spondylolisthesis, and retrospondylolisthesis. About 90% of people experience an episode of debilitating back pain at a later point in their lives. The majority of cases experienced are asymptomatic. Biopharmaceutical companies majorly target oral treatment and peripherally acting analgesics. Others in the pipeline involve muscle relaxants, sedatives, glucocorticoids, anticonvulsants, and antidepressants, among others.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises of a list of key sponsors with pipeline products for the concerned market.

Degenerative Disc Disease Clinical Trial Analysis by Phase and Status

  • The clinical trial analysis for degenerative disc disease indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials, as well as ones that have been terminated

Degenerative Disc Disease Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information regarding registered clinical trials in different countries, across several developed and emerging markets
  • The gold standard for structural disc degeneration is MRI. Apart from advances in regular medication to lessen back pain, efforts have been made to develop replacement spinal discs, grown from their stem cells. Several advancements are being made in therapeutics, and multiple technically advanced small- and medium-sized enterprises are progressing in the development of useful medications for back pain treatment

Key Sponsors in Degenerative Disc Disease Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you to understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Insights on regional- and country-level data
  • Dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy


1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Others

8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?



By submitting, you confirm that you agree to our privacy policy